- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
35
35 companies
Travere Therapeutics
Market Cap: US$3.8b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$40.29
7D
31.2%
1Y
166.6%
Zevra Therapeutics
Market Cap: US$632.9m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.39
7D
6.1%
1Y
42.1%
Axsome Therapeutics
Market Cap: US$9.7b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$182.97
7D
-0.7%
1Y
76.2%
Madrigal Pharmaceuticals
Market Cap: US$12.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$527.69
7D
0.5%
1Y
74.3%
Syndax Pharmaceuticals
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$23.33
7D
-4.5%
1Y
80.6%
Insmed
Market Cap: US$30.8b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$140.98
7D
-8.1%
1Y
97.9%
Ardelyx
Market Cap: US$1.6b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.30
7D
-0.5%
1Y
38.2%
Rhythm Pharmaceuticals
Market Cap: US$6.0b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$84.92
7D
-2.7%
1Y
43.4%
Capricor Therapeutics
Market Cap: US$2.0b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$35.34
7D
1.8%
1Y
154.4%
Aldeyra Therapeutics
Market Cap: US$107.1m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.68
7D
-6.1%
1Y
-27.6%
Pelthos Therapeutics
Market Cap: US$77.0m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$23.00
7D
0%
1Y
48.4%
ARS Pharmaceuticals
Market Cap: US$812.3m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$7.84
7D
-3.7%
1Y
-47.7%
AC Immune
Market Cap: US$298.6m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.98
7D
-9.7%
1Y
101.4%
CG Oncology
Market Cap: US$5.9b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$71.84
7D
6.8%
1Y
250.8%
Arcutis Biotherapeutics
Market Cap: US$3.0b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.40
7D
-6.7%
1Y
69.2%
Kiniksa Pharmaceuticals International
Market Cap: US$3.2b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$42.45
7D
-9.5%
1Y
112.0%
SIGA Technologies
Market Cap: US$341.0m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.57
7D
2.5%
1Y
-23.5%
Vera Therapeutics
Market Cap: US$3.0b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$40.06
7D
-9.7%
1Y
87.3%
Verrica Pharmaceuticals
Market Cap: US$109.6m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.32
7D
10.5%
1Y
35.0%
Belite Bio
Market Cap: US$6.5b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$165.23
7D
-3.9%
1Y
183.0%
Unicycive Therapeutics
Market Cap: US$187.5m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$7.21
7D
3.9%
1Y
15.7%
BeOne Medicines
Market Cap: US$35.3b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$312.31
7D
0.7%
1Y
23.6%
Praxis Precision Medicines
Market Cap: US$9.5b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$340.84
7D
-0.8%
1Y
847.3%
Journey Medical
Market Cap: US$141.8m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$4.92
7D
-6.5%
1Y
-33.4%
Fortress Biotech
Market Cap: US$74.7m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.23
7D
-7.9%
1Y
45.8%
Gyre Therapeutics
Market Cap: US$725.0m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.87
7D
0.4%
1Y
-8.9%
Fennec Pharmaceuticals
Market Cap: US$232.0m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.54
7D
4.6%
1Y
20.2%
Benitec Biopharma
Market Cap: US$479.2m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$13.18
7D
-0.5%
1Y
-4.4%
Mirum Pharmaceuticals
Market Cap: US$5.8b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$93.33
7D
-3.7%
1Y
136.7%
Prothena
Market Cap: US$580.9m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$10.67
7D
0.6%
1Y
11.8%
Legend Biotech
Market Cap: US$4.6b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$25.22
7D
34.9%
1Y
-26.9%
Geron
Market Cap: US$999.8m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.50
7D
-15.3%
1Y
6.4%
Protagonist Therapeutics
Market Cap: US$6.7b
Operates as a discovery and development company in the United States.
PTGX
US$105.89
7D
1.1%
1Y
130.9%
Inovio Pharmaceuticals
Market Cap: US$96.7m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$1.13
7D
1.8%
1Y
-38.9%
Dyadic International
Market Cap: US$32.0m
A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.
DYAI
US$0.84
7D
-3.9%
1Y
-30.9%